SCHEMBL3897476

SCHEMBL3897476

CS(=O)(=O)c1cccc(-c2nc(N)cc(-c3ccc(C(F)(F)F)cc3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.52
SDHB P21912 4/20 0.47
LMNA P02545 2/20 0.47
STAT3 P40763 2/20 0.47
STAT1 P42224 2/20 0.47
RAB9A P51151 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
TLR9 Q9NR96 2/20 0.47
MEN1 O00255 1/20 0.47
S1PR4 O95977 1/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
S1PR1 P21453 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PTGS1 P23219 4/20 0.45
ADORA2A P29274 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568019 0.87 SDHB (0.54) PTGS2SDHBLMNASTAT3STAT1
SCHEMBL3562889 0.81 SDHB (0.48) PTGS2SDHBLMNASTAT3STAT1
SCHEMBL3898550 0.79 ADORA2A (0.72) LMNAMEN1HPGDKMT2AHSD17B10
SCHEMBL28071862 0.79 ADORA2A (0.59) LMNAMEN1HPGDKMT2AHSD17B10
SCHEMBL4659067 0.78 SDHB (0.47) PTGS2SDHBLMNASTAT3STAT1
SCHEMBL3568722 0.77 PTGES2 (0.48) SDHBLMNASTAT3STAT1RAB9A
SCHEMBL3557424 0.77 LRRK2 (0.47) PTGS2PTGS1SYK
SCHEMBL3910159 0.76 ADORA2A (0.53) RAB9AMEN1HPGDKMT2AHSD17B10
SCHEMBL3560314 0.75 NR1H2 (0.50) PTGS2SDHBNR1H2NR1H3SYK
SCHEMBL3898780 0.75 ADORA2A (0.51) SDHBLMNAMEN1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524874-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-04-28 US disclosed
US-20050267163-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267163-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 PTGS2 176/4885SDHB 3696/4885LMNA 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.